Abingdon Health (LSE:ABDX) Gross-Profit-to-Asset % : 46.97% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Abingdon Health Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Abingdon Health's annualized Gross Profit for the quarter that ended in Dec. 2023 was £2.56 Mil. Abingdon Health's average Total Assets over the quarter that ended in Dec. 2023 was £5.44 Mil. Therefore, Abingdon Health's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 46.97%.

Abingdon Health Gross-Profit-to-Asset % Historical Data

The historical data trend for Abingdon Health's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abingdon Health Gross-Profit-to-Asset % Chart

Abingdon Health Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

22.06

44.67

18.75

-15.62

22.04

Abingdon Health Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					-6.84	-21.24	5.80	54.38	46.97

Competitive Comparison of Abingdon Health's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Abingdon Health's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abingdon Health's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Abingdon Health's Gross-Profit-to-Asset % falls into.

Abingdon Health Gross-Profit-to-Asset % Calculation

Abingdon Health's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	2.075	/	( (12.771	+	6.061)	/ 2 )
	=	2.075	/	9.416
	=	22.04 %

Abingdon Health's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	2.556	/	( (6.061	+	4.822)	/ 2 )
	=	2.556	/	5.4415
	=	46.97 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Abingdon Health Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Abingdon Health's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abingdon Health (LSE:ABDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abingdon Health PLC (LSE:ABDX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ

Website

https://www.abingdonhealth.com

Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.

Abingdon Health (LSE:ABDX) Headlines

No Headlines